In a rapidly evolving healthcare landscape, life sciences organizations face mounting challenges in market access—particularly when it comes to rare and specialty diseases. Fragmented data sources, delays in reporting, and lack of actionable insights often create barriers for patients in need of timely therapy.
In a recent interview with BioXconomy, Claritas Rx CEO Mike Fitzgibbons shares how Access Analytics is changing the game.
What is Access Analytics?
Access Analytics is an innovative platform designed to consolidate critical data from multiple sources—payers, specialty pharmacies, reimbursement hubs, and patient support programs—into a single, easy-to-use dashboard that updates daily. By bringing together this fragmented information, life sciences companies gain:
- Real-time visibility into brand performance
- Faster insights for teams to act on
- Reduced manual reporting and delays in decision-making
- Improved patient access and adherence, especially in complex rare disease markets
Why It Matters Now
For companies navigating specialty markets, every day matters when ensuring patients can start and stay on therapy. Traditional reporting methods often introduce lags and inefficiencies, but Access Analytics empowers organizations with actionable, data-driven insights that directly support patient outcomes.
Mike Fitzgibbons emphasizes that the future of market access lies in smarter, integrated platforms. Access Analytics not only streamlines day-to-day processes but also drives meaningful impact for patients and providers.
Learn More
Curious about how Claritas Rx is bridging gaps in access and revolutionizing analytics in life sciences?
- Read the full BioXconomy interview with Mike Fitzgibbons to explore the vision and innovation behind Access Analytics: Read the full story.
- See Access Analytics in action—schedule a demo today and discover how your organization can streamline access and support better patient outcomes.